VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 Mar 19, 2018
VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101 Mar 7, 2018
VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018 Mar 5, 2018
VistaGen Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018 Feb 27, 2018
VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder Jan 29, 2018
VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference Jan 22, 2018
VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder Jan 3, 2018
VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Dec 13, 2017
